TEAD1抗体;TEAD1 Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of TEAD1 expression in HeLa cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Immunoprecipitate (IP) analysis using the Antibody at 1:50 dilution. (wb at 1:6K dilution)    

  
  

TEAD1 (TEA Domain Transcription Factor 1) is a member of the evolutionarily conserved TEAD family of transcription factors, which plays a pivotal role in the Hippo signaling pathway. This pathway regulates organ size, tissue homeostasis, and cell proliferation by controlling the nuclear localization of transcriptional coactivators like YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif). TEAD1 binds to DNA through its conserved TEA domain, facilitating the recruitment of YAP/TAZ to activate target genes involved in cell survival, differentiation, and cancer progression.

TEAD1 is highly expressed in skeletal muscle, heart, and developing tissues, where it contributes to muscle-specific gene expression and cardiac development. Dysregulation of TEAD1 activity is implicated in various diseases, including cancers (e.g., breast, prostate, and glioblastoma), where its overexpression promotes tumor growth, invasion, and metastasis. Additionally, TEAD1 mutations or altered interactions with coactivators are linked to rare genetic disorders like Sveinsson’s chorioretinal atrophy.

TEAD1 antibodies are essential tools for studying its expression, localization, and function in biological systems. They are widely used in techniques such as Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP) to investigate TEAD1’s role in Hippo signaling and disease mechanisms. Specific antibodies targeting distinct epitopes (e.g., N-terminal or C-terminal regions) enable precise detection of TEAD1 isoforms or post-translational modifications. As TEAD1-YAP/TAZ inhibition emerges as a therapeutic strategy, these antibodies also aid in drug discovery and biomarker validation.